The antimanic-like effect of phenytoin and carbamazepine on methylphenidate-induced hyperlocomotion: Role of voltage-gated sodium channels

Fundamental and Clinical Pharmacology

Volumn 27, Issue 6, 2013, Pages 650-655

  Tonelli, Denise A G ^a   Pereira, Marcela ^a   Siba, Isadora P ^a   Martynhak, Bruno J ^a   Correia, Diego ^a   Casarotto, Plínio C ^b   Biojone, Caroline ^b   Guimarães, Francisco S ^b   Joca, Samia L R ^b   Andreatini, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal model; Anticonvulsant; Bipolar; Mania; Methylphenidate; Veratrine

Indexed keywords

CARBAMAZEPINE; CEVADINE; METHYLPHENIDATE; PHENYTOIN; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG MECHANISM; HYPERACTIVITY; HYPERLOCOMOTION; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMAL MODEL; ANTICONVULSANT; BIPOLAR; MANIA; METHYLPHENIDATE; VERATRINE;

ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHYLPHENIDATE; MICE; MOTOR ACTIVITY; PHENYTOIN; VERATRINE; VOLTAGE-GATED SODIUM CHANNELS;

EID: 84886558300     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12022     Document Type: Article

References (35)

1. Goodwin F.K., Jamison K.R. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, 2nd edn, Oxford University Press, New York, USA, 2007.
2. Cipriani A., Barbui C., Salanti G., et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet (2011) 378 1306-1315.
3. Ghasemi M., Farrokhi-Khajeh-Pasha Y., Ostovaneh M.R., Dehpour A.R. Lithium decreased endothelium-mediated, but not nonadrenergic noncholinergic, relaxation of guinea pig corpus cavernosum in vitro: a role for nitrergic system. Fundam. Clin. Pharmacol. (2011) 25 191-199.
4. Bourin M., Chenu F., Hascoët M. The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers. Curr. Drug Targets (2009a) 10 1052-1060.
5. Kalinowsky L.B., Putnam T.J. Attempts at treatment of schizophrenia and other nonepileptic psychoses with dilantin. Arch. Neurol. Psychiatry (1943) 49 414-420.
6. Mishory A., Yaroslavsky Y., Bersudsky Y., Belmaker R.H. Phenytoin as an antimanic anticonvulsant: a controlled study. Am. J. Psychiatry (2000) 157 463-465.
7. Mishory A., Winokur M., Bersudsky Y. Prophylactic effect of phenytoin in bipolar disorder: a controlled study. Bipolar Disord. (2003) 5 464-467.
8. Applebaum J., Levine J., Belmaker R.H. Intravenous fosphenytoin in acute mania. J. Clin. Psychiatry (2003) 64 408-409.
9. Shaldubina A., Einat H., Szechtman H., Shimon H., Belmaker R.H. Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J. Neural. Transm. (2002) 109 433-440.
10. Nemets B., Bersudsky Y., Belmaker R.H. Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. J. Clin. Psychiatry (2005) 66 586-590.
11. Shapira B., Nemets B., Trachtenberg A., Belmaker R.H. Phenytoin as an augmentation for SSRI failures: a small controlled study. J. Affect. Disord. (2006) 96 123-126.
12. Poncelet M., Brochet D., Chermat R., Simon P. Antidepressant-like effects of diphenylhydantoin in mice: involvement of α-adrenoceptors. Eur. J. Pharmacol. (1986) 120 133-135.
13. Bourin M., Chenu F., Hascoët M. Topiramate and phenytoin anti-immobility effect in the mice forced swimming test is reversed by veratrine: implication for bipolar depression treatment. Behav. Brain Res. (2009b) 205 421-425.
14. Codagnone F.T., Consoni F.T., Rodrigues A.L., Vital M.A., Andreatini R. Veratrine blocks the lamotrigine-induced swimming increase and immobility decrease in the modified forced swimming test. Prog. Neuropsychopharmacol. Biol. Psychiatry (2007) 31 1307-1311.
15. Prica C., Hascoet M., Bourin M. Antidepressant-like effect of lamotrigine is reversed by veratrine: a possible role of sodium channels in bipolar depression. Behav. Brain Res. (2008) 191 49-54.
16. Einat H. Modelling facets of mania: new directions related to the notion of endophenotypes. J. Psychopharmacol. (2006) 20 714-722.
17. Gould T.J., Keith R.A., Bhat R.V. Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav. Brain Res. (2001) 118 95-105.
18. Yang P., Singhal N., Modi G., Swann A., Dafny N. Effects of lithium chloride on induction and expression of methylphenidate sensitization. Eur. J. Pharmacol. (2001) 426 65-72.
19. Einat H., Yuan P., Szabo S.T., Dogra S., Manji H.K. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology (2007) 55 123-131.
20. Sabioni P., Baretta I.P., Ninomiya E.M., Gustafson L., Rodrigues A.L., Andreatini R. The antimanic-like effect of tamoxifen: behavioural comparison with other PKC-inhibiting and antiestrogenic drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry (2008) 32 1927-1931.
21. Barbosa F.J., Hesse B., de Almeida R.B., Baretta I.P., Boerngen-Lacerda R., Andreatini R. Magnesium sulfate and sodium valproate block methylphenidate-induced hyperlocomotion, an animal model of mania. Pharmacol. Rep. (2011) 63 64-70.
22. Moretti M., Valvassori S.S., Steckert A.V. et al. Tamoxifen effects on respiratory chain complexes and creatine kinase activities in an animal model of mania. Pharmacol. Biochem. Behav. (2011) 98 304-310.
23. Flaisher-Grinberg S., Einat H. Strain-specific battery of tests for domains of mania: effects of valproate, lithium and imipramine. Front. Psychiatry (2010) 1 10.
24. Voigt J.P., Morgenstern E. Comparative effects of carbamazepine, phenytoin, diazepam and clonazepam on inhibitory avoidance learning in mice. Psychopharmacology (1992) 108 131-135.
25. Arban R., Maraia G., Brackenborough K. et al. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav. Brain Res. (2005) 158 123-132.
26. Dencker D., Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav. Brain Res. (2010) 207 78-83.
27. Pereira M., Martynhak B.J., Baretta I.P., Correia D., Siba I.P., Andreatini R. Antimanic-like effect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene. Neurosci. Lett. (2011) 500 95-98.
28. Frey B.N., Andreazza A.C., Ceresér K.M. et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci. (2006) 79 281-286.
29. Belmaker R.H. The future of anticonvulsants in bipolar disorder. Bipolar Disord. (2010) 12 109-110.
30. Rosa A.R., Fountoulakis K., Siamouli M., Gonda X., Vieta E. Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neurosci. Ther. (2011) 17 167-177.
31. Ahmad S., Fowler L.J., Whitton P.S. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res. (2005) 63 141-149.
32. Valvassori S.S., Elias G., de Souza B. et al. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J. Psychopharmacol. (2011) 25 274-280.
33. Markowitz J.S., Patrick K.S. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin. Pharmacokinet. (2001) 40 753-772.
34. Gallagher P., Reid K.S., Watson S. Phenytoin, an anti-bipolar anticonvulsant: a potential anti-glucocorticoid mechanism? Int. J. Neuropsychopharmacol. (2006) 9 627-628.
35. Yamamura S., Hamaguchi T., Ohoyama K. et al. Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin. Epilepsy Res. (2009) 84 172-186.